In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv,. | January 7, 2023
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin.
Targeting the Most Common Viruses: A Novel Platform Technology Yields a New Drug that Could Treat Current and Future COVID-19 Variants Similar Efforts Show Promise against Influenza, Zika, West Nile, Hepatitis and Future Threats JERUSALEM, June 27, 2022 – ViroBlock, a startup company founded by.
Mrs. Jacobs-Lepor serves on the Board of Managers for U.S. Medical Innovations, LLC, a privately held FDA-registered biomedical device company focusing on the fields of plasma electrosurgical devices, robotic mini-invasive technology, and the eradication of cancer using cold plasma.
NEW YORK and JERUSALEM, June 2, 2022 /PRNewswire/ Today the Libra Group and the Hebrew University of Jerusalem (HU) announced the creation of Libra Fellows at Hebrew University, a 10-year